In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cygnus' Comeback in Non-Invasive Testing

Executive Summary

Cygnus is one of 1999's few great turnaround stories. A year ago, it was on the verge of collapse, but now it is about to get FDA approval of the first non-invasive glucose monitor for diabetes. Next, Cygnus needs to find a corporate partner without giving up too much, and to determine the true market potential of its device, the GlucoWatch Biographer, which got approved as an adjunct to, not a replacement for, traditional blood-glucose testing.
Advertisement

Related Content

Cracking Open the IPO Window for Pre-Commercial Device Companies
Cracking Open the IPO Window for Pre-Commercial Device Companies
Cracking Open the IPO Window for Pre-Commercial Device Companies
Cracking Open the IPO Window for Pre-Commercial Device Companies
Diabetes Monitoring Start-Ups:Building a Better Mousetrap or a Whole New Paradigm?
Diabetes Monitoring Start-Ups:Building a Better Mousetrap or a Whole New Paradigm?
Inverness Strengthens Its Hand; Cygnus Plays a Card

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001302

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel